Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Long COVID blood filter study pulled before it began

NCT ID NCT06637800

Disease control Sponsor: ExThera Medical Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study planned to test a blood filter device called Seraph 100 in 100 people with long COVID. The device was meant to remove harmful substances from the blood during two sessions on consecutive days. However, the study was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Seraph 100 blood filter device
What this could lead to
If it had worked, this could have pointed toward a new way to treat long COVID by filtering the blood.
What could go wrong
The study was withdrawn before any patients were enrolled, so we have no data on safety or effectiveness. The approach is experimental and unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Feb 2025

An estimate. Start dates often move.

Expected to finish

Apr 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects will be considered eligible for participation in the study if they meet all the following inclusion criteria: 1. Adult patients age of 18-85 (had 18th birthday but did not have 85th birthday). 2. History of COVID 19 infection established by positive polymerase chain reaction (PCR) test or by compatible clinical testing (e.g. rapid antigen, serum testing, or other relevant clinical documentation). 3. Persistent symptoms for 12 or more weeks after acute COVID 19 infection including fatigue and one or more of the following: myalgia or generalized aches and pains; joint pain; dizziness or unsteadiness; cognitive dysfunction (mental fog). 4. Patient (legally designated representative) has completed the Informed Consent process prior to enrollment into this study. 5. Patient (legally designated representative) is willing to comply with the study protocol - Exclusion Criteria: Subjects meeting any of the following criteria will not be recruited for the study: 1. History of heparin allergy. 2. History of heparin-induced thrombocytopenia. 3. Pregnancy or breastfeeding. 4. Life expectancy is less than 30 days. 5. The patient is currently enrolled in another drug or device trial. Patients who cannot tolerate placement of double-lumen catheter. 6. Unable to obtain informed consent from either patient or legally authorized representative (LAR)Any subject who, in the investigator's judgment, is considered unsuitable for participation in this trial. After verification of eligibility and signature of consent: 1\. The patient must be able to perform a hemoperfusion procedure with an apheresis machine.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID

Contacts and locations

Locations

  • Hospital Angeles Tijuana

    Tijuana, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.